注冊以創建關於儀器的通知
你所追隨的作者的經濟活動和內容
免費註冊 已有帳戶? 登入
Relay Therapeutics Inc是一家臨床級精密藥物公司。該公司致力於改變藥物發現過程,最初的重點是增强靶向腫瘤學中的小分子治療發現。該公司正在推進一條針對精確腫瘤學目標的藥物筦道,包括其主要候選產品RLY-4008、RLY-2608和RLY-1971。其RY-1971結合並穩定含有Src同源區二(SH2)的蛋白酪氨酸磷酸酶二(SHP2)的非活性構象。它的RLY-4008是成纖維細胞生長因數受體二(FGFR2)的抑制劑,為具有致癌性FGFR2的晚期實體瘤患者富集。該公司利用其Dynamo平臺專注於精確腫瘤學。它還推進了幾個早期項目,重點關注其他精確的腫瘤學和遺傳疾病目標。
名稱 | 年齡 | 成立於 | 主旨 |
---|---|---|---|
Mark Murcko | 61 | 2016 | Co-Founder & Director |
Douglas S. Ingram | 58 | 2019 | Independent Director |
Linda A. Hill | 64 | 2018 | Independent Director |
Jamilu E. Rubin | 57 | 2019 | Independent Director |
Laura K. Shawver | 63 | 2017 | Independent Director |
Pamela Munster | - | 2020 | Member of Oncology Advisory Board |
Jean-Charles Soria | 50 | 2020 | Member of Oncology Advisory Board |
Trever Bivona | - | 2020 | Member of Oncology Advisory Board |
Lillian L. Siu | - | 2020 | Member of Oncology Advisory Board |
George Daniel Demetri | 64 | 2020 | Member of Oncology Advisory Board |
Nikhil Wagle | - | 2020 | Member of Oncology Advisory Board |
Dejan Juric | - | 2020 | Member of Oncology Advisory Board |
Sekar Kathiresan | 50 | 2022 | Independent Director |
Alexis A. Borisy | 52 | 2015 | Co-Founder & Independent Chairman |
Sanjiv K. Patel | 50 | 2017 | CEO, President & Director |
你確定要封鎖 %USER_NAME%?
此舉將會令你與 %USER_NAME% 之間無法看見對方的Investing.com貼文。
%USER_NAME% 已成功加入你的封鎖清單
你剛解除此人的封鎖,必須等候 48 小時後才可再次封鎖。
我覺得這個評論是:
謝謝!
您的報告已被發送到我們的版主審核